| KOMISJA NADZORU FINANSOWEGO | ||||||||||||
| Raport bieżący nr | 4 | / | 2022 | |||||||||
| Data sporządzenia: | 2022-05-27 | |||||||||||
| Skrócona nazwa emitenta | ||||||||||||
| MILESTONE MEDICAL | ||||||||||||
| Temat | ||||||||||||
| Expanding medical indications for the CompuFlo Epidural Instrument and commencing disposable sales to a leading veterinary and academic institution | ||||||||||||
| Podstawa prawna | ||||||||||||
| Art. 17 ust. 1 MAR - informacje poufne. | ||||||||||||
| Treść raportu: | ||||||||||||
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company", “the Issuer"), today announced that it has commenced sales of its CompuFlo® Epidural instrument disposables at a leading veterinary and academic institution following a successful research study and evaluation. The veterinary institution has initially begun using the CompuFlo Epidural instrument for maxillary nerve block procedures in horses with plans to expand into epidural procedures. The CompuFlo Epidural instrument can provide fellow veterinarians and students greater accuracy through real-time verification of needle location when performing a maxillary nerve block. The name of the veterinary institution cannot be disclosed for confidentiality reasons. The Board of Directors of the Company is pleased to announce the adoption of CompuFlo Epidural instrument by this leading veterinary and academic institution. The Company is continually evaluating additional channels to commercialize its technology, including new medical indications. Veterinary medicine is just one example of another market that may benefit from CompluFlo Epidural instrument. The Board of Directors of the Company believes that the extensive prior studies, spanning epidural, peripheral nerve block, intra-articular, and veterinary use cases reinforce the enhanced safety, improved outcomes, economic benefits and broad market potential of the instrument. | ||||||||||||
| MESSAGE (ENGLISH VERSION) | |||
| MILESTONE MEDICAL INC | ||||||||||||||||
| (pełna nazwa emitenta) | ||||||||||||||||
| MILESTONE MEDICAL | ||||||||||||||||
| (skrócona nazwa emitenta) | (sektor wg. klasyfikacji GPW w W-wie) | |||||||||||||||
| NJ 07039 | . | |||||||||||||||
| (kod pocztowy) | (miejscowość) | |||||||||||||||
| South Orange Avenue Livingston | 220 | |||||||||||||||
| (ulica) | (numer) | |||||||||||||||
| +11 973 535 2717 | +11 973 535 2829 | |||||||||||||||
| (telefon) | (fax) | |||||||||||||||
| (e-mail) | (www) | |||||||||||||||
| 27-5484393 | ||||||||||||||||
| (NIP) | (REGON) | |||||||||||||||
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |||||
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | ||
| 2022-05-27 | Keisha Harcum | Controller | Keisha Harcum | ||
